Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Leqembi Now Approved in China: Eisai/Biogen
January 10, 2024
- BioCryst Japan to First Focus on Orladeyo Promotion, Eager to Set Up Own Sales Team: Local Head
January 9, 2024
- Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
- Organon Japan Gets Approval for Fertility Med Follistim after Re-Filing
January 9, 2024
- Trelegy Frontrunner in GP Promotion, Dayvigo Defends Title in HP List in October: Intage
January 9, 2024
- Boehringer Grabs Rights to Kyowa Kirin’s Fibro-Inflammatory Disease Drug
January 9, 2024
- US FDA Accepts Stelara Biosimilar for Review: Meiji
January 9, 2024
- Equa, Betanis and More Brands Gird for Generic Entry in 2024; Xarelto Contenders Too?
January 5, 2024
- After New Year’s Quake, Wholesalers See Challenges in Drug Delivery to North Part of Noto Peninsula
January 5, 2024
- Moderna Seeks Japan Nod for Pre-Filled Syringe Form of COVID Vaccine
January 5, 2024
- After GCP Scandal, Medipharma Begins Bankruptcy Proceedings
January 5, 2024
- Astellas, China Biotech Hook Up on Bispecific Macrophage Engagers
January 5, 2024
- South Korean Partner to Locally Manufacture Xocova: Shionogi
December 28, 2023
- Healios, Nobelpharma Ink Basic Deal for Cell Therapy Alliance in ARDS
December 28, 2023
- Amylyx Gears Up to Bring New ALS Drug to Japan Market: Country Chief
December 27, 2023
- Eisai, Oita University Develop Wearable Sensor to Predict Brain Aβ Buildup
December 27, 2023
- iPSC-Based Parkinson’s Therapy Cleared for Investigator-Led Trial in US: Sumitomo
December 27, 2023
- Daiichi’s HER3 ADC Gets Priority Review in US for 3rd Line EGFR-Mutated NSCLC
December 26, 2023
- Mochida Files Label Expansion for Inhaled Treprost in Japan
December 26, 2023
- Sandoz to Take Over Distribution Rights to Japan’s 1st Humira Biosimilar
December 26, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…